Boston Scientific Shares Dip 0.24% as FDA Scrutiny Clashes with Bullish Upgrades and 228th Rank in $430M Trading Volume

On August 29, 2025, Boston Scientific (BSX) closed at $105.75, down 0.24%, with a trading volume of $0.43 billion, ranking 228th in the market. The stock faced mixed sentiment amid regulatory scrutiny and strategic updates.

Recent news highlighted safety concerns linked to BSX’s defibrillator leads, with reports of 17 device-related injuries or deaths. The FDA intensified monitoring, raising questions about product reliability. Conversely, Mizuho upgraded its price target for BSX to $118, citing growth potential in robotics and device innovation. Analysts noted robust earnings from MedSurg and Cardiovascular segments, though Clariti sales weakness in Asia-Pacific and e-commerce softness weighed on short-term performance.

Backtest data showed BSX outperformed the S&P 500 over 12 months (30.78% vs. 15.53%) and 5 years (157.13% vs. 84.16%). Year-to-date returns of 18.11% trailed peers like Medtronic (MDT) and Stryker (SYK), which posted higher gains. The stock’s forward P/E of 35.59 and PEG ratio of 1.84 indicated mixed valuation metrics compared to industry benchmarks.